Pall Enters Laboratory Water Market With New Cascada Lab Water System

Food and Healthcare Press Releases Tuesday March 1, 2005 16:46
EAST HILLS, N.Y.--(BUSINESS WIRE)--Feb. 28, 2005--

Purified water is an essential and growing requirement of research and diagnostic laboratories. Water quality can wreak havoc on sensitive equipment andtest results. To meet demanding life science and analytical testingrequirements, Pall Corporation (NYSE: PLL), the global leader infiltration, separations and purification, announced that it isbringing its water purification expertise to the laboratory marketwith the introduction of the Pall Cascada(TM) Lab Water Systems. TheCascada point-of-use system provides optimum water quality to supportdiverse laboratory needs from the most critical, sensitiveapplications through general-purpose use.

"As the lab market becomes increasingly complex and demanding,customers need trustworthy providers that are deeply entrenched inwater purification," says Ken L. Harris, President Pall Life SciencesNew Technology. "Pall's entry into this marketplace combines more thana half century experience in the development of the most advancedwater purification technologies used by a host of industries worldwidewith our in-depth, extensive knowledge and understanding of thediverse application needs of the laboratory markets we serve."

The Cascada System enables laboratories to achieve the highestpurity water through a series of separation and purification steps ina single box on demand. Four polishing systems, with customizedconfigurations to meet a wide range of sensitive application requiresfor high quality ultrapure water, are available. A pretreatment systemis also available to protect and extend the life of the polishers,which is particularly important in cases where there is poor feedwaterquality.

Expanding Market with Unmet Needs

"The lab water market continues to expand and rapid technologicalgrowth in regions of the world, such as Asia and Latin America, stillhave many unmet needs. We are confident we will be one of the leadingproviders of point-of-use laboratory water systems in the nearfuture," says Mr. Harris.

The global laboratory water systems and consumables market isestimated at $250 million dollars, growing at a rate of about 8percent annually.

"Pall selected the best available technology for our new system tomonitor and protect the quality of the output water at the least costof ownership for academic, clinical, biopharmaceutical andpharmaceutical research laboratories," Mr. Harris adds. "The newCascada system is merely the tip of the iceberg for Pall in thismarketplace."

The Company plans to extend its dominant position in waterpurification by utilizing its proprietary technologies to continue torefine systems and lead in the growing, changing and ever moredemanding laboratory water market.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing fieldof filtration, separations and purification. Pall's business isorganized around two broad markets: Life Sciences and Industrial. TheCompany provides leading-edge products to meet the demanding needs ofcustomers in biotechnology, pharmaceutical, transfusion medicine,semiconductors, water purification, aerospace and broad industrialmarkets. Total revenues are $1.8 billion. The Company headquarters arein East Hills, New York with extensive operations throughout theworld. Visit Pall at www.pall.com.

Forward Looking Statement

This release contains "forward-looking statements" as defined inthe Private Securities Litigation Reform Act of 1995. These statementsare based on current Company expectations and are subject to risks anduncertainties which could cause actual results to differ materially.Such risks and uncertainties include, but are not limited to:fluctuations in foreign currency exchange rates; regulatory approvaland market acceptance of new technologies; changes in product mix andproduct pricing and in interest rates and cost of raw materials; theCompany's success in enforcing its patents and protecting itsproprietary products and manufacturing techniques and its ability toachieve the savings anticipated from its cost reduction initiatives;global and regional economic conditions and legislative, regulatoryand political developments; and domestic and international competitionin the Company's global markets. Additional information regardingthese and other factors is available on the Web at www.pall.com and isincluded in the Company's reports filed with the U.S. Securities andExchange Commission. Copies of such reports can be obtained, withoutcharge, at www.sec.gov.

Management uses certain non-GAAP measurements to assess Pall'scurrent and future financial performance. The non-GAAP measurements donot replace the presentation of Pall's GAAP financial results. Thesemeasurements provide supplemental information to assist management inanalyzing Pall's financial position and results of operations. Pallhas chosen to provide this information to facilitate meaningfulcomparisons of past, present and future operating results and as ameans to emphasize the results of ongoing operations.

Editors Note:
Product photos and additional information can be found onwww.pall.com/corporate_35507.asp
CONTACT: Pall Corporation
Patricia Iannucci, 516- 801-9100
E-mail: piannucci@pall.com
Source: Business Wire Press Release

Latest Press Release

Walgreens Boots Alliance and Microsoft establish strategic partnership to transform health care delivery

- Companies aim to improve health outcomes and lower overall costs with enhanced digital and retail experiences and an R&D commitment to build health care solutions through seven-year agreement Walgreens Boots Alliance Inc. (WBA) and Microsoft Corp....

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems. (Logo:...

MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's...

Gift of Life Donor Program is U.S. Leader in Saving Lives

For the 11th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement organization (OPO), coordinating the most life-saving organs for transplant among all 58 U.S. OPOs. Gift of Life broke two national records in 2018,...

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Licensing rights are worldwide excluding US, Canada, Japan and South AmericaHelsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in 136 countries worldwide, today...

Related Topics